Non-Executive Director appointment

RNS Number : 3330E

ConvaTec Group PLC

27 February 2020

 

ConvaTec Group PLC  

Non-Executive Director appointment

Reading, United Kingdom (27 February 2020)  

ConvaTec Group Plc ("ConvaTec" or "the Company") announces the appointment of Brian May as a Non-Executive Director of the Company and member of the Audit and Risk Committee and Remuneration Committee with effect from 2 March 2020.

Brian has extensive financial and international business experience. He has overseen significant strategic growth initiatives resulting in both organic and inorganic growth and sustained shareholder returns over the long term through strong capital allocation.

Brian was formerly Chief Financial Officer of Bunzl plc from 2006 to 2019 and, prior to that, he held a number of senior management finance roles with Bunzl, including divisional Finance Director, Group Treasurer and Head of Internal Audit. He qualified as a Chartered Accountant with KPMG in 1988.

John McAdam, Chairman of ConvaTec, commented:

"I am delighted that Brian is joining our Board. He has considerable financial experience and expertise. Furthermore, he has a detailed understanding of the challenges and opportunities that arise as a result of transformational change. As we focus on pivoting to sustainable and profitable growth, I am confident that he will make a valuable contribution to the Board."

Brian is currently a Non-Executive Director of United Utilities Group plc and Chair of its Audit and Treasury Committees

.

No other information requires disclosure in accordance with Listing Rule 9.6.13.

This announcement is made in accordance with Listing Rule 9.6.11R(1).

Enquiries:

Analysts and Investors

Mark Reynolds, Director Investor Relations                                                                        [phone]

[e-mail]

Media

Buchanan: Charles Ryland/Chris Lane/Vicky Hayns      [phone]  

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has established market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.  www.convatecgroup.com .

 

END

 

 

BOAKKOBBFBKKDBB